| Variable | Categories | Albuminuria | OR (95% CI) | p-value | |
| Yes (n = 24) | No (n = 36) | ||||
| n (%) | n (%) | ||||
| Age (Years) | <60 | 8 (33.3) | 5 (13.9) | 1 | 0.081 |
| ≥60 | 16 (66.7) | 31 (86.1) | 3.10 [0.87 - 11.04] | ||
| Sex | Male | 14 (58.3) | 27 (75) | 0.47 [0.15 - 1.41] | 0.320 |
| Female | 10 (41.7) | 9 (25) | 1 | ||
| Medication | ARB use |
|
| 1.00 [0.15 - 6.48] | 1.000 |
| ACEI use | 5 (20.8) | 3 (8.3) | 2.90 [0.62 - 13.48] | 0.176 | |
| Metformin use | 2 (8.3) | 5 (13.9) | 0.56 [0.10 - 3.17] | 0.516 | |
| NSAIDS use | 2 (8.3) | 2 (5.6) | 1.56 [0.23 - 11.79] | 0.326 | |
| Diuretics use | 3 (12.5) | 2 (5.6) | 2.43 [0.37 - 15.58] | 0.352 | |
| Herbal med use | 8 (33.3) | 5 (13.9) | 3.10 [0.87 - 11.04] | 0.081 | |
| TFV prodrug | TDF | 22 (91.7) | 20 (55.6) | 8.80 [1.80 - 43.15] | 0.007 |
| TAF | 2 (8.3) | 16 (44.4) | 1 | ||
| Comorbidities | Hypertension | 7 (29.2) | 5 (13.9) | 2.55 [0.70 - 9.29] | 0.155 |
| Diabetes | 2 (8.3) | 5 (13.9) | 0.56 [0.10 - 3.17] | 0.516 | |
| HDV | 7 (29.2) | 13 (36.1) | 0.73 [0.24 - 2.22] | 0.577 | |
| BMI (kg/m2) | <18 | 2 (8.3) | 1 (2.8) | 3.18 [0.27 - 37.94] | 0.356 |
| ≥18 | 22 (91.7) | 35 (97.2) | 1 | ||
| Duration of TFV therapy | <36 | 6 (25) | 1 (2.8) | 1 | 0.028 |
| ≥36 | 18 (75) | 35 (97.2) | 11.7 [1.30 - 104.53] | ||
| ALAT, IU/L | >36 | 8 (83.3) | 5 (13.9) | 1.32 [0.49 - 3.72] | 0.598 |
| ≤36 | 11 (45.8) | 19 (58.2) | 1 | ||
| ASAT, IU/L | >35 | 12 (50) | 17 (47.2) | 1.18 [0.40 - 3.12] | 0.833 |
| ≤35 | 12 (50) | 19 (52.8) | 1 | ||
| Hep B Viral load, IU/mL | >2000 | 12 (50) | 14 (40) | 1.50 [0.54 - 4.27] | 0.448 |
| ≤2000 | 12 (50) | 21 (60) | 1 | ||